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Summary 
An immunodominant epitope of myelin basic protein (MBP), VHFFKNIVTPRTP (p87-99), 
is a major target of T  cells in lesions of multiple sclerosis (MS) and in experimental  allergic 
encephalomyelitis (EAE). T cells found in EAE lesions bear the same amino acids in the third 
complementary determining region of the T cell receptor (TCK) as those found in MS lesions. 
We analyzed the trimolecular interactions between MBP p87-99, dass II major histocompatibility 
complex (MHC), and TCK, and designed soluble inhibitors for therapy. F, N, I, and V at positions 
90, 92, 93, and 94 interact with MHC, whereas K, T, and P at positions 91, 95, and 96 interact 
with TCK. The peptides, p87-99195T>A]  and p87-99196P>A] could compete more effectively 
with p87-99 for binding to MHC and could antagonize the in vitro response ofT cells to p87-99 
more effectively than p87-99191K>A].  However, only p87-99191K>A] prevented and reversed 
EAE, indicating that the extent of  MHC or TCK competition does not predict success  in treating 
EAE. To elucidate the mechanism of inhibition  of EAE, draining lymph node cells from rats 
immunized with the native peptide alone or together with each of the three TCR antagonists 
were challenged in vitro with p87-99.  Administration of p87-99191K>A],  but not p87-99 
[9ST>A]  or p87-99196P>A],  reduced the production of tumor necrosis factor (TNF)- oe and 
interferon (IFN) 3'. IFN-3" and TNF-ol are two cytokines that are critical in the pathogenesis 
of EAE and MS. 
E 
xperimental allergic encephalomyelitis  (EAE)  1 is a T cell- 
mediated autoimmune disease of the central  nervous 
system (1, 2). The TCK recognizes  peptide bound to an MHC 
molecule (3). Several  groups, including ours, have  formulated 
nonimmunogenic peptides based on the sequence of myelin 
basic protein (MBP) that bind class II MHC to a much greater 
extent than the native, encephalitogenic peptides of MBP, 
and that prevent EAE when given in adjuvant (4-9). We now 
extend this approach in order to develop TCR. antagonists 
that would prevent and reverse EAE, when induced by MBP 
p87-99. 
The rationale for pursuing inhibitors of the MBP p87-99 
follows from some serendipitous findings (10) regarding  a 
major set of TCR rearrangements in multiple sclerosis (MS) 
brain lesions. Using PCK on reverse-transcribed mRNA, we 
1 Abbreviations used in this paper: EAE, experimental  allergic encephalo- 
myelitis;  MBP, myelin  basic  protein; MS, multiple  sclerosis;  PLP,  proteolipid 
protein; SI, stimulation index. 
analyzed  TCK gene rearrangements directly from brain plaques 
of MS patients,  who are HLA DK2 (10), and from spinal 
cords of rats with EAE after immunization with p87-99 (11). 
T cells with the amino acid motif LRG in the CDR3 region 
(10-13) are found in EAE lesions in the Lewis rat and in MS 
lesions. Remarkably, a cytotoxic T cell clone specific  for MBP 
p87-99 from an MS patient who was HLA DR2 has the 
same amino acid motif, LRG, in the CDK3 of its TCK-3 
chain (12, 14). Thus, T cell clones in Lewis rats and in MS 
patients, which express this CDR3 motif, all have specificity 
for MBP p87-99, VHFFKNIVTPKTP (p87-99) (10, 11, 14). 
MBP p87-99  has further importance because it is an im- 
munodominant epitope of  MBP in MS patients who are HLA 
DR2 (10, 11,  14,  15). 
We have analyzed the putative sites where MBP p87-99 
interacts with MHC and TCR in the Lewis rat. Based on 
these studies, we designed different peptide  antagonists  of 
MBP 87-99 that interfere with the encephalitogenic T cells. 
We have been able to design  a peptide inhibitor that an- 
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soluble form, can reverse ongoing EAE with clinical paral- 
ysis.  This  peptide  also  reduces production  of two  critical 
cytokines involved in the pathogenesis of EAE and MS, TNF-oe 
and IFN-'y. This report extends the approach of using TCP, 
antagonists  to prevent EAE (4, 5, 8,  16). Recently, Franco 
et al.  (16) showed that they could prevent EAE with a pool 
of TCR antagonist peptides given in equimolar amounts with 
the encephalitogenic peptide 139-151 of proteolipid protein 
(PLP) in CFA. We sought to apply this approach to a clini- 
cally relevant paradigm in which we attempted to reverse es- 
tablished paralysis with a TCR antagonist that could be given 
in a  soluble form. 
Materials and Methods 
Rats.  Female  Lewis rats,  •6  wk  old, were purchased from 
Harlan Sprague Dawley (Indianapolis,  IN). 
Peptide Antigens.  Human MBP p87-99, VHFFKNIVTPRTP, 
and a series of 13 p87-99 analogues  that differ from the original 
MBP peptide by a single alanine substitution, as well as MBP pl-20 
and MBP p68-86, were synthesized with a free carboxylic acid at 
the COOH terminus on a peptide synthesizer (model 9050; Mil- 
liGen, Burlington, MA) by standard 9-fluorenylmethoxycarbonyl 
chemistry.  MBP pl-20 is acetylated at the NH2 terminus. Peptides 
were purified by HPLC. Structure was confirmed by amino acid 
analysis and mass spectroscopy. Only peptides that were >95% pure 
were used in our study. 
Immunizations  and Active EAE Induction.  MBP peptides were 
dissolved in PBS and emulsified with an equal volume of IFA sup- 
plemented  with  4  mg/ml  heat-killed MIcobacterium  tuberculosis 
H37Ra in oil (Difco Laboratories,  Detroit, MI).  Rats were im- 
munized subcutaneously in the hind foot pads with 0.1 ml of the 
emulsion and were monitored daily for clinical signs by an observer 
blind to the treatment protocol. EAE was  scored as follows:  0, 
clinically normal; 1, flaccid tail; 2, hind limb paralysis; and 3, front 
and hind limb paralysis. 
Culture Media.  DME (GIBCO BILL, Gaithersburg, ME)) sup- 
plemented with 2-ME (5  x  10 -s M), t-glutamine (2 mM), so- 
dium pyruvate (1 raM), penicillin  (100 #/ml), streptomycin (100 
#g/ml), and 1~  autologous Lewis rat serum was used as a stimu- 
lation medium. Resting medium was identical to the stimulation 
medium without autologous serum and with the addition of 10% 
FCS (GIBCO BILL) and 12.5% supernatant of Con A-stimulated 
splenocytes as a source of T cell growth factors. Con A superna- 
tant was prepared as described elsewhere (1). 
Antigen-specific T Cell Proliferation Assays.  Lewis rats were im- 
munized with different MBP peptides  as described  above. 9-10 d 
later,  draining lymph node cells were suspended  in stimulation 
medium and cultured in U-shape 96-well microcuhure plates for 
72 h at 37~  in humidified air containing 6.5% CO2, at a con- 
centration of 2  x  l0  s cells/well. For the antigen-specific  prolifer- 
ation assay ofT celt lines and clones, ceils were plated at a concen- 
tration  of 2  x  104 cells/well with  l0  s  irradiated  (2,500  rad) 
thymocytes as accessory cells together with different concentra- 
tions of ,ntigen. Each well was pulsed with 2/~Ci of [3H]thymi- 
dine (sp act 10 Ci/mmol) for the final 6 h. The cultures were then 
harvested on fiberglass falters and the proliferative response expressed 
as cpm _+ SD or as stimulation index (SI) (mean counts per minute 
test cultures divided by mean counts per minute control cultures). 
Long-term T Cell Lines and Clones.  Antigen-specific long-term 
T cell lines and dones were deriv&l by use of the method developed 
by Ben-Nun et al. (1). Lewis rats  were immunized as described 
previously.  9-10 d later, draining lymph node calls were cultured 
(107/ml) for 72 h  in stimulation medium together with  10-20 
/~mol of the immunizing peptide. The cells were then collected, 
washed, and cultured for a phase in resting medium. After an addi- 
tional 5-8 d, cells were collected and either tested for antigen-specific 
proliferation or cultured for additional cycles. For cloning of antigen- 
specific T cell lines, resting T cells were cultured in 96-well microcul- 
ture plates at a concentration of 0.3 cells/well with 5  x  10  s ir- 
radiated (2,500 tad) thymocytes as accessory cells and 10-20 #mol 
of antigen.  After  three  to  five stimulation  cycles, plates  were 
screened, clones were transferred to 24-well flat bottom plates, and 
restimulated. Before use in the study,  all clones were recloned by 
use of the method described above. 
MHC Binding Assay.  An assay that characterizes  the binding 
of peptides to MHC molecules on living APCs was used (17, 18). 
Spleen cells were cultured in DME supplemented with 10% FCS 
(Hyclone Laboratories,  Logan, UT) in standard polystyrene petri 
dishes (100  x  15 mm; Baxter Healthcare Corp., Deerfield, IL) in 
a  37~  incubator  containing  6.5%  CO2  for 3  h.  Thereafter, 
nonadherent cells were removed, and the plates were washed three 
times with PBS. Adherent cells were collected with a cell scraper 
(Falcon,  Franklin Lakes, NJ). The binding of p87-99 analogues 
was measured by use of a fluorescence  assay as follows:  5  x  10  s 
splenic adherent cells in staining buffer containing 0.1% BSA in 
PBS were mixed with different concentrations ofp87-99 analogues 
in individual wells of U-shape 96-well microculture plates and in- 
cubated at 370C in a 6.5% CO2 incubator.  I h later, biotinqabeled 
p87-99 (10 #mol) was added to culture wells for 4 h. The cells 
were washed three times with the staining buffer before PE-strep- 
tavidin (Becton Dickinson & Co., San Jose,  CA) was added as a 
second-step reagent (10 #l/well, 20 min) along with labeled mAb 
reacting with rat MHC class II I-A (0.4 #l/well,  OX-6;  Phar- 
Mingen,  San Diego, CA),  The cells were washed twice before 
cytofluorographic analysis on a FACScan  |  (Becton Dickinson & 
Co.). The fluorescence intensity was calculated by subtracting the 
fluorescence  obtained  from  OX-6-positive  cells  stained  with 
PE-streptavidin only from the fluorescence obtained with biotin- 
labeled p87-99 plus phycoerythrin-streptavidin. The percentage of 
inhibition was calculated  and is presented as ICs0 values. 
T  Cell Antagonism  Proliferation Assay.  T cell antagonism was 
detected in  a  prepulsed proliferation assay as described by De 
Magistris  et al. (19) with some modifications.  Antigen-presenting 
spleen cells were 7 irradiated (3,000 tad) and incubated with 0.2 IzM 
of the native peptide in stimulation medium at a concentration 
of 107 cells/well in 10-ml tissue culture plates  for 2.5 h at 37~ 
in humidified air containing 6.5%  CO2.  Spleen cells were then 
washed  and  recultured in  individual wells  of U-shape  96-well 
microculture plates (5  x  l0  s cells/well) with 5  x  104 resting anti- 
p87-99 T  cells with different concentrations of antagonist pep- 
tides, ranging from 10 .4 #M to 10 -1 #M, for an additional 60 h. 
Each well was pulsed with 1 #Ci of [SH]thymidine  (sp act 10 Ci/ 
retool) for the final 18 h. The cultures were then harvested on fiber- 
glass filters and the proliferative response expressed as cpm _+ SD 
or SI (mean cpm test cultures divided by mean cpm control cultures). 
Cytokine Determination.  Draining lymph node cells were stimu- 
lated in vitro (10 7 calls/m1) with different concentrations of an- 
tigens. After 12, 24, 48, and 72 h of stimulation, supernatants were 
collected for cytokine detection, and cells were immediately frozen 
for KNA extraction. IFN-y was determined after 48 h by use of 
a rat IFN-'y ELISA kit (GIBCO BRL). TNF-~x was measured after 
24 h by use of ELISA kits (Genzyme Corp., Cambridge, MA) suit- 
able for mice and rats. The kits were used according to manufac- 
turers' instructions. 
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Determination of  Amino Acids Involved  in the Binding ofp87-99 
to RT.D  1 (IF.) MHC Class II Molecules.  A single injection 
of guinea pig MBP emulsified in CFA induces EAE in the 
Lewis rat (1). The T cell response is directed against a major 
encephalitogenic region  encompassed by  residues  68-86 
presented in  association  with RT.B 1 (I-A)  MHC  class II 
molecules (20), and to a second encephalitogenic region en- 
compassed by a residues 87-99 of MBP restricted by RT.D 1 
(I-E) MHC class II gene products (20, 21). A T ceU line specific 
for p87-99, named L87-99, was selected. The proliferative 
response of the line was blocked to a substantial degree with 
an anti-I-E (OX-17, 2.5/zg/ml), but not an anti-I-A (OX-6, 
2.5/~g/ml) mAb (response to MBP p87-99:54,350  +  840 
with  anti-I-A blocking vs.  17,120  _+  310  with  anti-I-E 
blocking [data shown as cpm __  SE, background: 3,420  __ 
330 cpm, p <0.001]).  A panel of 13 alanine-substituted pep- 
tides based on MBP p87-99 was synthesized (Table 1). These 
analogues were tested in a competition assay with the native 
peptide for binding to I-E on APCs (Fig. 1, Table 1). Four 
of these peptides, p87-99190F>A],  p87-99192N>A], p87-99 
[93I>A], and p87-99194V>A], were poor competitors with 
the native peptide on binding to autologous APCs (ICso 
>200/~M for each of the analogues, compared with ICs0 = 
14/~M for the native peptide) (Table 1). These results indi- 
cate that these four positions are putative binding sites to 
I-E (see Fig. 3). 
Amino Acids Necessary  for Induction of EAE.  Each of 13 
alanine-substituted analogues was tested for its ability to in- 
duce EAE (Table 1). Immunization with the native peptide, 
as well as 6 of the other 13 mutated peptides, p87-99187V>A], 
p87-99188H>A], p87-99189F>A], p87-99193I>A], p87-99 
[97R>A],  and p87-99198T>A],  elicited  EAE in 34 of 36 
Lewis rats. In contrast, the three peptide analogues, p87-99 
[91K>A], p87-99195T>A],  and p87-99196P>A], with an 
ICs0 for binding to I-E that was similar to native peptide 
(Table 1, Fig.  1), (range of ICs0 14-21 compared with ICs0 
native peptide of 14), never induced EAE in Lewis rats (Table 
1, incidence of 0.6 for each of these analogues compared with 
6/6 for the native peptide). This suggests that lysine, threo- 
nine, and proline at positions 91, 95, and 96 are essential for 
TCR recognition of p87-99. 
All three nonencephalitogenic peptide analogues that bound 
to  I-E with  ICs0 in the range of native peptide, p87-99 
[91K>A],  p87-99195T>A],  and  p87-99196P>A],  either 
stimulated a weak response to p87-99 or failed to elicit a 
proliferative response in L87-99 (Fig. 2). This further confirms 
our observation that the lysine, threonine, and proline at po- 
sitions 91, 95, and 96 are essential for effective TCR binding 
to p87-99 (Figs. 2 and 3). Consequently, each of these ana- 
logues might serve as a therapeutic TCR antagonist capable 
of blocking EAE. The peptides p87-99197R>A] and p87-99 
[98T>A] were encephalitogenic and could evoke a prolifera- 
tive response in draining lymph node T cells after immuni- 
zation with native p87-99 (Table 1), though they failed to 
elicit a significant proliferative response in L87-99 (Fig. 2). 
This indicates that L87-99 does not include all potential T 
cell clones capable of mounting a pathogenic T cell response. 
Comparison of the TCR Antagonists  p87-99195T>A], p87-99 
[96P>A], and p87-99191K>A].  Using an assay developed 
by De Magistris et al.  (19) to detect TCR antagonists, we 
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Figure  1.  MHC binding compe- 
tition between  alanine  analogues 
and  MBP p87-99.  The ability  of 
each of the 13 alanine-substituted 
analogues at different concentrations 
from 0 to 200 #M to inhibit the 
binding of 10 #M of biotin-labeled 
native  peptide  was  measured  and 
presented as the percentage of inhi- 
bition of mean relative binding. The 
ICs0 values are shown in Table 1. Table  1.  The Effect of Single Alanine Substitutions on Relative MHC 1I Binding and Encephalitogeneity of the Peptide 
ICs0  DLNC  Line 87-99  Active EAE 
I-E binding  proliferative  proliferative 
Peptide  (/zM)*  response*  responses  Incidence  Duration 
87  88  89  90  91  92  93  94  95  96  97  98  99  d 
p87-99  V  H  F  F  K  N  I  V  T  P  K  T  P  14  ++++  +++++  6/6  7 
p87-99  [87V>]  A  31  +  +  +  +  +  +  +  +  +  6/6  7 
p87-99  [88H>A]  A  14  +  +  +  +  +  +  +  +  +  6/6  7 
p87-99  [89F>A]  A  11  +  +  +  +  +  +  +  6/6  7 
p87-99  [90F>A]  A  >200  +  -  0/6  0 
p87-99  [91K>A]  A  21  +  -  0/6  0 
p87-99  [92N>A]  A  >200  +  +  +  +  +  1/6  4 
p87-99  [93I>A]  A  >200  -  +  +  +  6/6  7 
p87-99  [94V>A]  A  >200  -  +  +  2/6  5 
p87-99  [95T>A]  A  14  +  -  0/6  0 
p87-99  [96P>A]  A  14  +  +  -  0/6  0 
p87-99  [97R>A]  A  20  +  +  -  4/6  7 
p87-99  [9ST>A]  A  14  +  +  +  +  +  +  +  6/6  7 
p87-99  [99P>A]  A  10  +  +  +  +  +  +  -~ +  +  3/6  5 
* ICs0 values were calculated from Fig.  1. 
* Kats were immunized with p87-99. 9 d later, the proliferative response against the native peptide, as well as against each of the 13 peptide ana- 
logues, was determined in a proliferation assay. The maximal response was graded as follows:  -, SI <1;  +, 1 <SI <1.5;  + +, 1.5 <SI <2;  + + +, 
2 <SI <3;  + + + +, 3 <SI <3.5;  + + + + +, 3.5 <SI <4. 
S The proliferative response of line L87-99 to its native peptide as well as to all the peptide analogues was recorded (Fig. 2). These results are sum- 
marized here as follows:  -, SI <20;  +, 20 <SI <30;  + +, 30 <SI <40;  + + +, 40 <SI <50;  + + + +, 50 <SI <75;  + + + + +, 75 <SI <85. 
tested  p87-99191K>A],  p87-99195T>A],  and  p87-99- 
[96P>A] for their capacity to inhibit the response of L87-99 
to native peptide MBP p87-99.  A  concentration  of 20 #M 
of p87-99 was found to be optimal for induction  of a max- 
imal  proliferative  response  in  L87-99  (Fig.  2).  We  tested 
TCR antagonism  at  a  concentration  of 0.2  #M  since  this 
concentration elicited a significant response in L87-99 (Fig. 
4,  SI  =  23.0  _+  1.1  with  a background  of 306  cpm).  All 
three analogues antagonized  the response of L87-99 to na- 
tive peptide when added at a concentration  of 0.0001-0.01 
/zM in the proliferation assay (Fig. 4). In fact, p87-99195T>A] 
and p87-99196P>A]  were found to be stronger antagonists 
than p87-99191K>A]. At a concentration as low as 0.0001/~M 
of p87-99195T>A]  or p87-99196P>A],  >85% inhibition of 
the proliferative response of the encephalitogenic line to its 
native peptide  (SI  =  2.6  +  0.2  and  1.9  _+  0.2  compared 
with SI  =  23  _+  1.1, p  <0.001)  (Fig.  5, B  and  C) was ob- 
served. A  100-fold greater concentration of peptide p87-99- 
[91K>A] was required for a similar degree of inhibition (SI  = 
4.7  +  2.7  compared  with  SI  =  23.0  +  1.1,  p  <0.001) 
(Fig.  4  A).  These  findings  could  be  explained  in  part  by 
the fact that both p87-99195T>A]  and p87-99196P>A]  are 
stronger  competitors  of the native peptide  on binding  I-E 
than p87-99191K>A]  (IC50  =  14 for each of these peptides 
compared with  IC50  =  21  for p87-99191K>A])  (Fig.  1). 
All three peptide analogues antagonized the proliferative 
response of the encephalitogenic  line L87-99  (Fig.  4).  We 
also tested each of these antagonists on an anti-p87-99 CD4 + 
T  cell clone selected from this line.  A  representative experi- 
ment  with  this  clone  revealed  a  proliferative  response  of 
12,336  _+  440  cpm with  a background  of 458  cpm in  re- 
sponse to 0.2 #M of p87-99.  Each of the putative antago- 
nists inhibited this response. At 0.001 #M of either p87-99 
[91K>A], p87-99195T>A],  or p87-99196P>A],  proliferation 
was reduced  to 6,450  _+  530,  2,458  _+  670,  and  3,430  _+ 
175  cpm,  respectively. 
p87-99191K>A],  but neither p87-99195T>A]  nor p87-99 
[96P>A],  Prevents EAE in an Epitope-specific Manner.  Since 
p87-99195T>A]  and p87-99196P>A]  displayed stronger in 
vitro  blocking  capacities  for  I-E  and  TCR  than  p87-99 
[91K>A], they were both expected to inhibit EAE better than 
p87-99191K>A].  Interestingly, only p87-99191K>A]  (0/12 
with EAE vs. 24/24  groups g  and h, p  <0.001)  could pre- 
vent EAE when coimmunized with native peptide at a  1:1 
molar ratio (Table 2, group h compared with g  and J3.  Nei- 
ther p87-99195T>A]  (12/12 with EAE) nor p87-99196P>A] 
(12/12  with  EAE) could prevent EAE when coimmunized 
with  native peptide  at a  1:1 molar ratio  (Table 2).  p87-99 
[91K>A] reduced the incidence and severity of disease even 
at  a  3:1  excess of the pathogenic  peptide  (3/6  with  EAE; 
Table 2,  group  i). 
The NH2-terminal fragment of MBP (pl-20)  was used as 
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Figure  2.  Proliferative response of L87-99 to different alanine-substituted analogues. The proliferative response of L87-99 in response to the different 
alanine-substituted analogues was determined in a proliferation assay and shown as counts per minute. All standard deviations were less than  _+10%. 
a control peptide, since in Lewis rats this peptide is not en- 
cephalitogenic  (Table  2,  group  l).  Coimmunization  of 
the pl-20 fragment together with p87-99 did not prevent 
EAE in any of the immunized rats  (6/6 with EAE;  Table 
2,  group m). 
In Lewis rats there are two encephalitogenic regions of MBP, 
p68-86 and p87-99. We studied the specificity of EAE inhi- 
bition by p87-99191K>A].  Rats were coimmunized with ei- 
ther p87-99 plus p87-99191K>A]  or p68-86 plus p87-99 
I  MHC 
I  Ill 
87  88  89  90  91  92  93  94  95  96  97  98  99 
I  "~  I 
Figure  3.  Putative binding site of p87-99 to MHC and TCK. Putative 
binding sites of p87-99 to MHC and TCK were inferred according to 
the results summarized in Table  1. 
[91K>A] (at a 1:1 molar ratio for each combination), or with 
each  of the native peptides alone.  Prevention of EAE by 
p87-99191K>A] was specific for disease induced with p87-99 
(18/18  with EAE vs. 0/12 with EAE, p  <0.001), but not 
with disease induced with p68-86 (6/6 with EAE; Table 2, 
groups a, h,j, and k). Thus, p87-99191K>A]  prevents EAE 
in an epitope-specific  manner. 
Mechanisms of Inhibition of EAE by p87-99191K>A].  To 
further investigate the mechanism behind EAE resistance, rats 
were immunized with native peptide p87-99 alone, or to- 
gether with either peptide p87-99191K>A], p87-99195T>A], 
or p87-99196P>A] at a 1:1 molar ratio with the native pep- 
tide,  p87-99.  9 d later,  some of the rats were killed, and 
proliferative responses against the native peptide were deter- 
mined in the draining lymph nodes (Fig. 5, A and B). Some 
rats from each of the groups remained in cages for further 
observation for development of paralysis. All rats (6/6) im- 
munized with the native peptide alone or p87-99 together 
with either p87-99195T>A] or p87-99196P>A] developed 
EAE. None of the rats coimmunized with p87-99191K>A] 
and p87-99 developed EAE (0/6, p <0.001). Nevertheless, 
all groups displayed a very similar SI (Fig. 5 B) in the prolifer- 
ative response against  the native peptide, p87-99,  in their 
draining lymph node cells. We noted that the proliferative 
response to p87-99 (in absolute counts per minute) observed 
in draining lymph node cells from rats immunized with the 
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p87-99. The proliferative  response of L87-99 to 0.2/~M of the native 
peptide was antagonized  by 0.0001-0.01 #M of either p87-99191K>A] 
(A), p87-99195T>A] (B), or p87-99196P>A] (C). Results are shown  as 
SI  +_  SE. 
native peptide alone was lower than the proliferative response 
seen in lymph nodes from rats coimmunized with p87-99 
[91K>A],  p87-99195T>A],  or p87-99196P>A]  (Fig. 5, A 
and B). These results indicate that EAE resistance did not 
result from induction of  unresponsiveness  to the native, patho- 
genic peptide when rats were coimmunized  with native pep- 
tide and p87-99191K>A]. 
We hypothesized  that the protective and nonprotective  TCR 
antagonists might differentially alter the cytokine profile in 
encephalitogenic  T cells after stimulation with the pathogenic 
peptide. The draining lymph node cells  from rats coimmunized 
with p87-99  and p87-9919LK>A] produced markedly re- 
duced  levels of TNF-o~ and  IFN-'y  compared  with those 
immunized with the native peptide  or coimmunized with 
p87-99195T>A] or p87-99196P>A]. For IFN-% we observed 
the following amounts in response to 100 #M p87-99 in vitro 
(Fig. 5 C):  1,750  _+  80 pg/ml when p87-99191K>A]  was 
coimmunized with native p87-99,  compared with 5,200  _+ 
300 pg/ml for p87-99195T>A]  plus  p87-99  (p <0.0015); 
7,200  _+  580  pg  /ml  for  p87-99196P>A]  plus  p87-99 
(p <0.001); and 4,200  _+  100 pg/ml for native peptide alone 
(p <0.003). For TNF-o~, we observed the following amounts 
in response to 100 #M p87-99 in vitro (Fig. 5 D):  32  _+ 
3 pg/ml when p87-99191K>A] was coimmunized with na- 
tive  p87-99,  compared  with  81  _+  4  pg/ml  for p87-99 
[95T>A] plus p87-99 (p <0.003); 72  _+ 4 pg/ml for p87-99 
[96P>A]  plus  p87-99  (p  <0.004);  and  62  _+  1  pg/ml 
when p87-99 was given alone (p <0.005).  Thus the TCR 
antagonist  capable of blocking EAE,  p87-99191K>A],  re- 
duced TNF-ol and IFN-'y production, whereas the other TCR 
antagonists did not influence  the production of these cytokines. 
Reversal  of  EAE by Soluble  Peptide  Analogues.  From aclinical 
perspective, the use of a soluble form of a therapeutic peptide 
analogue would be more practical than the use of such a pep- 
tide emulsified in CFA. We therefore explored the therapeutic 
potential of soluble p87-9919LK>A]. In experiment 1 (Table 
3), a single i.p. inoculation with 2 mg/ml of either p87-99 
or p87-99191K>A] 2 d after transfer of L87-99 reduced the 
incidence of EAE (for example, 5/5 control with EAE, day 
5,  vs.  0/5  with  p87-99,  vs.  0/5  with  p87-99 
[91K>A], p <0.002).  Neither p87-99195T>A]  nor p87-99 
[96P>A]  prevented EAE. 
In experiment two (Table 3), two i.p. injections of 2 mg/ml 
each were given on days 2 and 4 after transfer of L87-99. 
Peptides p87-99,  p87-99191K>A],  and p87-99196P>A] re- 
duced the incidence of  EAE: on day 7 in the group of  control 
rats, 6/6 had EAE, but when p87-99 was given intraperi- 
toneally in solution, 0/6 had EAE (p <0.001 compared with 
control animals),  when p87-99[K91>A]  was given intra- 
peritoneally in solution,  0/6 had EAE (p <0.001 compared 
with control rats), and when p87-99196P>A] was given in- 
traperitoneally in solution, 2/6 had EAE (p <0.15 compared 
with control rats).  In comparison,  when p87-99195T>A] 
was given intraperitoneally  in solution,  6/6 had EAE. 
Disease reversal was attempted in a third experiment in 
which 15 rats were inoculated with 15  x  106 L87-99  cells 
to induce EAE and were randomly distributed into three sub- 
groups of 5 rats each. 1 d later, two of these groups  were 
given intraperitoneaUy 2 mg/ml of p87-99191K>A] dissolved 
in PBS. All 15 rats had hind limb paralysis 4-5 d after disease 
induction. On day 5, one group received another 2 mg/ml 
of p87-99191K>A].  All 5 rats who received this second in- 
fusion  of p87-99191K>A]  went into  complete remission 
within 24-36 h, with no residual signs of paralysis, whereas 
paralysis persisted in all other rats for another 4-5 d. 
In a fourth experiment (Fig. 6),  18 rats were given 107 
L87-99 T cells, and all 18 developed  hind limb paralysis  within 
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Figure  5.  Cytokine  production  al- 
tered by peptide analogues. The pro- 
liferative  response (A and B), IFN-7 
(C), and TNF-~ (D) production in 
draining lymph node cells from rats 
immunized  with p87-99 =lone (-A-), 
or  together with p87-9919LK>A] 
(-B-), p87-99195T>A] (-C]-), or 
p87-99196P>A] (-A-). Proliferative 
responses were analyzed either as 
counts per minute _+ SE (A) or by 
SI (B). 
5 d. The paralyzed rats were given a single injection (2 mg/ml) 
of soluble p87-99191K>A],  p87-99195T>A],  or PBS. Al- 
though all positive control PBS-immunized rats, as well as 
those immunized with p87-99195T>A] (6/6 in each group), 
continued to show hind limb paralysis for the following 4 d, 
all rats (6/6) treated with the p87-99191K>A] analogue went 
into complete remission within 36 h without further signs 
of paralysis  (p <0.015)  (Fig.  6). 
Discussion 
Activation of CD4 §  T  cells follows engagement of the 
TCR by a peptide bound to class II MHC (3), together with 
a costimulatory signal from the APCs (22). Optimal engage- 
ment leads to proliferation, cytokine induction, and effector 
function. Previous studies have shown that analogues of a 
native peptide in which a critical TCR binding site was al- 
tered may perturb the effector functions of the T  cell,  in- 
cluding  alterations  in  proliferative  capacity  and  cytokine 
production (22-25).  In this study, we have continued our 
studies on the design of peptide-based TCR antagonists to 
reverse the prototypic model of CD4 + T cell-mediated au- 
toimmunity, EAE (9). 
We and others (4, 5, 8, 9) have previously formulated non- 
pathogenic peptide analogues that bind class II MHC to a 
much greater extent than the native encephalitogenic pep- 
tides of MBP and prevent EAE in a specific manner. It has 
been assumed that the main, if not the only, mechanism by 
which these peptides inhibit EAE is by successfully competing 
with the native peptide for binding to MHC class II (26). 
However, further evidence suggested that mechanisms other 
than MHC competition might be involved in this process. 
In the Lewis rat, the major encephalitogenic region encom- 
passes residues 68-86 presented in association with RT.B 1 
(I-A) MHC  class II molecules (20).  Arthritogenic T  cells 
recognize their autoantigen in association with RT.B 1 gene 
products as well (27).  Wauben et al.  (27)  have used high 
MHC-binding peptide analogues of either the encephalito- 
genic or arthritogenic peptides to show that arthritis could 
be blocked only by the arthritogenic peptide analogue, whereas 
EAE could be blocked by either peptide. These findings im- 
plied  that  mechanisms  distinct  from MHC  blocking  are 
operative in this form of immunotherapy (27). 
In (PL/JxSJL) mice, EAE is induced by immunization with 
MBP peptide Ac1-11. Q  and K at positions 3 and 4 in this 
MBP epitope are putative TCR-  and MHC-binding  sites, 
respectively (8). Mutations in peptides with either single ala- 
nine substitutions at position 4K or double substitutions at 
both 3Q and 4K resulted in nonencephalitogenic peptides 
with an enhanced capacity to compete with the native Acl-ll 
2233  Karin et al. Table  2.  MBP p87-9919IK>A]  Prevents EAE Induced b  7  the Native Peptide in an Epitope-specific Manner* 
EAE 
Immunizing peptides  Peptide 2/ 
peptide 1  Mean maximum 
Group  Peptide 1  Peptide 2  ratio  Incidence  Duration  clinical score 
d 
a  p87-99  None  18/18'  7  2.4  _+  0.2 
b  p87-99191K>A]  None  0/12s  0  0 
c  p87-99195T>A]  None  0/12  0  0 
d  p87-99196P>A]  None  0/12s  0  0 
e  p87-99  p87-99  1:1  6/6  8  3  •  0 
f  p87-99  p87-99195T>A]  1:1  12/12s  7  1.7  •  0.1 
g  io87-99  p87-99196P>A]  1:1  12/I2S  6  2.2  •  0.2 
h  p87-99  p87-99191K>A]  1:1  0/12 s  0  0 
i  p87-99  p87-99191K>A]  1:3  3/6  6  1.2  •  0.5 
j  p68-88  None  6/6  7  3  •  0 
k  p68-88  p87-99191K>A]  1:1  6/6  7  3  •  0 
1  pl-20  None  0/6  0  0 
m  pl-20  p87-99  1:1  6/6  7  2.5  +  0.2 
* Rats were immunized  with p87-99/CFA alone  or together  with different  peptide  analogues  at either a 1:1 or a 1:3 molar ratio. EAE was monitored 
daily as follows: score 1, paraplegia of the tail; score 2, paralysis of hind limbs; score 3, paralysis of hind and front limbs. 
* Results of three consecutive  experiments done under the same conditions; six rats in each experiment. 
S Results of two consecutive experiments done under the same conditions; six rats in each experiment. 
for binding to MHC. Interestingly,  only Ac1-ll[4K>A], and 
not the double-substituted analogue Ac1-1113Q>A,  4K>A] 
could evoke a proliferative response in encephalitogenic clones 
selected with the native peptide (5, 8). Only Acl-ll[4A] pep- 
tide could inhibit EAE when coadministered in adjuvant with 
the native peptide (5,  8).  These data strongly suggest that 
factors other than MHC competition are involved, though 
alternative mechanisms remain elusive. Our results also dem- 
onstrate that blockade and reversal of EAE are based on mech- 
anisms that are not explained by MHC competition. T cell 
unresponsiveness is not seen with the therapeutic peptide ana- 
logue used in this study. Of the three peptide analogues, mu- 
tated at different TCR interaction sites, only the analogue 
with the lowest affinity for MHC (p87-99191K>A]) could 
prevent actively induced EAE and reverse ongoing disease after 
adoptive transfer. 
De Magistris et al. (19) have demonstrated that peptide 
analogues, mutated in a TCR putative binding site, may dis- 
play variable  degrees  of antagonism toward a collection of 
T  cell clones with similar antigen specificity and MHC re- 
striction (19, 28, 29).  A recent paper by Franco et al.  (16) 
examined some peptide analogues,  mutated in their TCR 
binding sites for their potential capability to prevent EAE, 
when induced by p139-151  of PLP in vivo. No single mu- 
tated peptide could antagonize the response of the majority 
of these PLP clones in vitro. Therefore, they used a pool of 
TCR antagonists to block the proliferative response of  different 
T cells specific for PLP p139-151. They successfully prevented 
EAE induction when the antagonists were coadministered 
in adjuvant at the time of immunization (16). Neither dis- 
ease reversal nor the use of water soluble inhibitors in vivo 
was demonstrated. 
We tested the  therapeutic capabilities  of three  alanine- 
substituted analogues,  mutated in a putative TCR binding 
site. All three peptide analogues antagonized the prolifera- 
tive response of the encephalitogenic line L87-99 (Fig.  4), 
as well as an anti-p87-99 CD4 + T  cell clone selected from 
this line. Nevertheless,  only one of these antagonists could 
prevent and reverse EAE. In addition, in draining lymph node 
cells from rats immunized with the inhibitory analogue, there 
was no reduction in the proliferative  response to the patho- 
genic peptide p87-99 (Fig.  5). This reinforces the idea that 
EAE resistance  does not result from antigen unresponsive- 
ness to p87-99. We hypothesized that the protective and non- 
protective antagonists may differentially alter the cytokine 
profile in the encephalitogenic T cells. Indeed, we have demon- 
strated that only rats coimmunized with p87-99 and the pro- 
tective p87-99191K>A], and not p87-99195T>A] or 87-99 
[96P>A],  could downregulate the production of the Thl 
cytokines, TNF-ol and IFN-% 
The role of TNF-oe in EAE has been studied extensively 
(30-34).  Administration of TNF-cz augmented EAE (31), 
whereas anti-TNF-ol therapy abrogated the disease (33, 34). 
The capacity of autoimmune T  cell clones  to induce EAE 
was found to be corrdated with their ability to produce TNF-cz 
(32).  In different strains of rats susceptibility to EAE was 
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Peptide Analogues 
Group 
EAE incidence  o  O 
LIJ 
Soluble peptide Day 5 Day 6 Day 7 Day 9 
2 mg/ml 
Single inoculation 
(day 2)* 
a  None  5/5  5/5  5/5  1/5 
b  p87-99  0/5  1/5  2/5  0/5 
c  p87-99191K•A]  0/5  1/5  2/5  0/5 
e  p87-99195T>A]  5/5  5/5  5/5  1/5 
f  p87-99196P>A]  3/5  4/5  4/5  0/5 
Double inoculation 
(days 2 and 4)* 
a  None  4/6  6/6  6/6  1/6 
b  p87-99  0/6  0/6  0/6  0/6 
c  p87-99191K>A]  0/6  0/6  0/6  0/6 
e  p87-99195T>A]  2/6  4/6  6/6  1/6 
f  p87-99196P>A]  0/6  1/6  2/6  0/6 
*  Experiment 1: Rats were inoculated  intraperitoneally  with 10  x  106 
activated L87-99 cells (day 0) and were randomly  distributed into five 
subgroups of five  rats each. 2 d later, four of these groups were injected 
intraperitoneally  with either p87-99, p87-99191K>A], p87-99195T>A], 
or p87-99196P>A]. EAE was monitored daily  as described in Table 2. 
Experiment 2: Rats were inoculated  intraperitoneally  with 10  x  106 
activated L87-99 cells (day 0) and were randomly  distributed into five 
subgroups of six rats each. Two injections  of 2 mg/ml of either p87-99, 
p87-99191K~,A], p87-99[95T>A], or p87-99196P>A] were given in- 
traperitoneally on days  2 and 4. EAE was monitored daily  as described 
in Table 2. 
correlated with TNF-ot expression by astrocytes (30). Elevated 
levels of TNF-ct in the cerebrospinal fluid have been associated 
with disease progression in MS (35). 
The role of IFN-3, in EAE is enigmatic. It is a potent acti- 
vator of monocytes and macrophages and an inducer of class 
II expression  on astrocytes.  Blockade of MHC class II pre- 
vents and reverses EAE  (36,  37).  In EAE,  astrocytes  may 
present MBP to encephalitogenic T  cells (38).  In contrast, 
intraventricular administration of IFN-3, suppressed EAE in 
Lewis rats (39), perhaps by eliciting the activation of macro- 
phages, thus resulting in elevated levels of TGF45 secretion, 
which downregulates TNF-c~ production and thereby sup- 
presses EAE (40). Anti-IFN-3, antibody also exacerbates EAE 
(41, 42).  Administration of IFN-T to MS patients induces 
exacerbations  (43). 
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Figure  6.  Reversal  of EAE by 
soluble  peptide  therapy.  Rats  were 
immunized  with 1071.87-99 cells 
to induce transferred EAE. 5 d 
later, when clinical  disease  was ap- 
parent, rats were randomly  dis- 
tributed into three subgroups of 
six rats each. These groups were 
then  injected intraperitoneally 
with 2 mg/ml of either p87-99- 
[91K~A] (~),  p87-99195T~A  l 
(-I-), or PBS ('-C~). EAE was 
graded daily  (mean _+ SE) as de- 
scribed in Table 2. 
IFN-3, and TNF-c~ together exhibit a synergistic effect on 
enhancing expression  of adhesion molecules on endothelial 
cells (44), and thus act in concert to promote the inflamma- 
tory process in the central nervous system. Adhesion mole- 
cules such as very late antigen 4 and vascular cell adhesion 
molecule are critical in the pathogenesis of EAE (45). These 
roles for TNF-ot and IFN-q, may explain why p87-99191K~A], 
in  contrast  to  p87-99195T~A]  or  p87-99196P>A]  p87, 
prevented  and reversed EAE. 
Finally, it is remarkable that the injection of a TCR an- 
tagonist in soluble form could reverse ongoing paralysis in 
EAE. The mechanism of this inhibition is unclear at present, 
but direct binary engagement of the TCR by antigen may 
be a possibility, even though this idea is perhaps  heretical 
(46). Binary interactions between superantigen and TCR have 
been demonstrated (47).  Alternatively, soluble MHC-pep- 
tide complexes might act to inhibit EAE by engaging TCR 
without adequate second signals  (48). 
There is therapeutic potential for the delivery of soluble 
TCR antagonists devoid of adjuvant or MHC, given the dom- 
inance of T cell responses to certain peptides in MS (10, 11). 
It is noteworthy that the peptide p87-99191K~A] abrogates 
the cytotoxicity of a human T  cell clone,  derived from an 
MS patient who is HLA DR2,  that is cytotoxic for MBP 
p87-99. This clone has the CDR3 motif  LRG in the TCR-B 
chain (49).  Whether suppression  of this immune response 
in an MS patient will alter the course of disease can only 
be answered in a clinical  trial. 
It is noteworthy that clinical trials involving the adminis- 
tration of MBE have been undertaken in patients with MS 
(50, 51). In one of these trials,  some patients became sensi- 
tized to the administered MBP (51). Animal testing of native 
peptides of MBP given subcutaneously in adjuvant (52) or 
orally (53) has been promising. We propose here that paren- 
teral administration of modified native peptides devoid of en- 
cephalitogenic potential that antagonize TCR involved in the 
disease will be an advantageous strategy for the therapy of MS. 
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